Key facts
- Notable investors include Mission BioCapital, BioInnovation Institute, Sahsen Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Skape Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Skape Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Skape Bio
Developer of a drug discovery platform designed for pharmaceutical companies to unlock G protein-coupled receptors. The company's AI-driven platform unites generative protein design, native receptor biology, and scalable in-cell screening, enabling drug developers to access unreachable therapeutic targets and achieve precise receptor modulation.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2025
- Employees
- 9
- Website
- skape.bio/
- Ownership
- Privately Held (backing)
Skape Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Skape Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Skape Bio in its N-PORT filings yet. We sweep new filings monthly.